Novonesis Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Novonesis heeft een totaal eigen vermogen van €11.0B en een totale schuld van €2.0B, wat de schuld-eigenvermogensverhouding op 18.1% brengt. De totale activa en totale passiva bedragen respectievelijk €15.3B en €4.2B. De EBIT Novonesis is €525.0M waardoor de rentedekking 15.7 is. Het heeft contanten en kortetermijnbeleggingen van €260.8M.

Belangrijke informatie

18.1%

Verhouding schuld/eigen vermogen

€1.99b

Schuld

Rente dekkingsratio	15.7x
Contant	€260.80m
Aandelen	€11.01b
Totaal verplichtingen	€4.25b
Totaal activa	€15.25b

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( €1.8B ) 0Q4U } overtreffen de korte termijn passiva ( €1.6B ).

Langlopende schulden: De kortetermijnactiva van 0Q4U ( €1.8B ) dekken de langetermijnschulden ( €2.6B ) niet.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 15.7% ) 0Q4U wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van 0Q4U is de afgelopen 5 jaar gedaald van 36.2% naar 18.1%.

Schuldendekking: De schuld van 0Q4U wordt goed gedekt door de operationele kasstroom ( 44.8% ).

Rentedekking: De rentebetalingen op de schuld van 0Q4U worden goed gedekt door EBIT ( 15.7 x dekking).

Novonesis Balans Gezondheid

Financiële gezondheid criteriumcontroles 5/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Novonesis A/S to Report First Half, 2025 Results on Aug 13, 2025

Novonesis A/S Announces Board Changes

First half 2024 earnings released: EPS: €0.14 (vs €0.67 in 1H 2023)

Novonesis Approves Interim Dividend for 2024, Payable on September 3, 2024

Now 10% overvalued after recent price rise

Now 21% overvalued after recent price rise

Now 22% overvalued after recent price rise

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

New minor risk - Financial position

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings released

Now 21% undervalued after recent price drop

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Second quarter 2023 earnings released

Novozymes A/S Announces Change to the Executive Leadership Team

First quarter 2023 earnings released: EPS: kr.2.83 (vs kr.3.00 in 1Q 2022)

Upcoming dividend of kr.6.00 per share at 1.8% yield

Independent Chairman recently bought kr.1.0m worth of stock

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings released

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Less than half of directors are independent

Third quarter 2022 earnings released

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Second quarter 2022 earnings released: EPS: kr.2.92 (vs kr.2.85 in 2Q 2021)

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

First quarter 2022 earnings released: EPS: kr.3.00 (vs kr.3.17 in 1Q 2021)

Less than half of directors are independent

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Upcoming dividend of kr.5.50 per share

Full year 2021 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Revenue Guidance for 2022

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Third quarter 2021 earnings released

Second quarter 2021 earnings released

Novozymes A/S Provides Earnings Guidance for the Full Year 2021

First quarter 2021 earnings released

Novozymes A/S Reaffirms Sales Guidance for the Year 2021

Univar Solutions and Novozymes® Partner to Bring Innovative, Sustainable Biotechnology Products to Customers in the United States and Canada

Novozymes Acquires Data Science Platform of Biota to Strengthen Microbiome R&D Capabilities in Probiotic Development

Novozymes A/S (CPSE:NZYM B) acquired the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc.

Upcoming Dividend of kr.5.25 Per Share

New 90-day high: kr.383

Novozymes A/S Announces Executive Appointments, Effective April 2021

Full year 2020 earnings released

Revenue misses expectations

Fmc Corporation Collaborates with Novozymes A/S to Co-Develop Enzyme Solutions

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Microbiome Labs.

Novozymes A/S (CPSE:NZYM B) entered into an agreement to acquire Microbiome Labs for $250 million

Novozymes A/S to Report Fiscal Year 2020 Results on Jan 01, 2021

New 90-day low: kr.338

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse